TRGC2: Potential Drug Target and Biomarker (G6967)

Target Name: TRGC2

NCBI ID: G6967

TRGC2

Other Name(s): TRGC2(2X) | T cell receptor gamma constant 2 | TCRGC2 | TRGC2(3X)

TRGC2: Potential Drug Target and Biomarker

TRGC2 (TRGC2(2X)) is a protein that is expressed in various tissues of the body, including the brain, heart, lungs, and gastrointestinal tract. It is a member of the TRG family of transmembrane proteins, which are known for their role in cell signaling.

One of the unique features of TRGC2 is its ability to form a complex with the protein p120GTP, which is a known modifier of the protein kinase A. This complex formation is important for the regulation of various cellular processes, including cell signaling, cell division, and cell survival.

In addition to its role in cell signaling, TRGC2 has also been shown to play a role in the regulation of inflammation and immune responses. This is important because many diseases, including cancer and neurodegenerative disorders, are characterized by chronic inflammation and an imbalance in the immune system.

Due to its involvement in both cell signaling and inflammation, TRGC2 has been identified as a potential drug target and biomarker. Studies have shown that inhibiting TRGC2 can lead to a reduction in the expression of genes involved in cell signaling and inflammation, which could have therapeutic benefits for a variety of diseases.

In addition to its potential therapeutic applications, TRGC2 has also been the subject of research to determine its potential as a biomarker for certain diseases. For example, studies have shown that TRGC2 levels can be affected by a variety of factors, including genetic variations, environmental factors, and exposure to certain drugs. This makes TRGC2 a potentially useful biomarker for the diagnosis and prognosis of certain diseases.

Overall, TRGC2 is a protein that has important roles in both cell signaling and inflammation. Its potential as a drug target and biomarker make it an attractive target for further research and development. As the understanding of TRGC2 continues to evolve, it is likely that new therapeutic approaches will emerge that can harness its power for the treatment of a variety of diseases.

Protein Name: T Cell Receptor Gamma Constant 2

Functions: Constant region of T cell receptor (TR) gamma chain that participates in the antigen recognition (PubMed:24600447). Gamma-delta TRs recognize a variety of self and foreign non-peptide antigens frequently expressed at the epithelial boundaries between the host and external environment, including endogenous lipids presented by MH-like protein CD1D and phosphoantigens presented by butyrophilin-like molecule BTN3A1. Upon antigen recognition induces rapid, innate-like immune responses involved in pathogen clearance and tissue repair (PubMed:28920588, PubMed:23348415). Binding of gamma-delta TR complex to antigen triggers phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) in the CD3 chains by the LCK and FYN kinases, allowing the recruitment, phosphorylation, and activation of ZAP70 that facilitates phosphorylation of the scaffolding proteins LCP2 and LAT. This lead to the formation of a supramolecular signalosome that recruits the phospholipase PLCG1, resulting in calcium mobilization and ERK activation, ultimately leading to T cell expansion and differentiation into effector cells (PubMed:25674089). Gamma-delta TRs are produced through somatic rearrangement of a limited repertoire of variable (V), diversity (D), and joining (J) genes. The potential diversity of gamma-delta TRs is conferred by the unique ability to rearrange (D) genes in tandem and to utilize all three reading frames. The combinatorial diversity is considerably increased by the sequence exonuclease trimming and random nucleotide (N) region additions which occur during the V-(D)-J rearrangements (PubMed:24387714)

The "TRGC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRGC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets